Pfizer Reports Fourth-Quarter And Full-Year 2012 Results; Provides 2013 Financial Guidance

Oncology unit revenues increased 11% operationally in comparison with fourth-quarter 2011. Revenues were positively impacted by the launches of Inlyta and Xalkori in the U.S. and certain other developed markets. Revenues were negatively impacted by approximately $44 million, or 13%, due to the shift in the reporting of international Aromasin revenues to the Established Products unit beginning January 1, 2012.

Consumer Healthcare unit revenues increased 17% operationally in comparison with fourth-quarter 2011, primarily due to the addition of products from the acquisitions of Ferrosan Consumer Health in December 2011 and Alacer Corp. in February 2012 as well as strong growth of Advil and Centrum in the U.S.

Adjusted Expenses ⁽²⁾ , Adjusted Income ⁽²⁾ and Adjusted Diluted EPS ⁽²⁾ Highlights

		Fourth-Quarter Selected Costs and Expenses
($ in millions) (Favorable)/Unfavorable		2012				2011				Change				Foreign Exchange			Operational
Adjusted Cost of Sales (2)		$	3,106			$	3,083			1	%			8	%		(7	%)
As a Percent of Revenues			20.6	%			19.1	%		N/A				N/A			N/A
Adjusted SI&A Expenses (2)			4,658				5,173			(10	%)			(1	%)		(9	%)
Adjusted R&D Expenses (2)			2,000				2,318			(14	%)			(1	%)		(13	%)
Total		$	9,764			$	10,574			(8	%)			1	%		(9	%)

See end of text prior to tables for notes.

« First ‹ Previous 1 2 3 4 5 6 7 8 9 ... Next › Last »